You are here

Drug Screen Can Detect 9 Drug Classes, Gets Clearance

Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy

Quidel has received 510(k) clearance from the FDA to market the Quidel Triage® TOX Drug Screen, 94600, a fluorescence immunoassay for the determination of the presence of drugs and/or metabolites in human urine. The test is to be used with Quidel’s Triage® MeterPro instrumented system.

Drug abuse in the U.S. continues to be a major social and economic problem. Opiates, cocaine, THC, and amphetamines are recognized by the Substance Abuse and Mental Health Services Administration (SAMHSA) as the most commonly abused illegal drugs. Prescription drugs such as benzodiazepines, tricyclic antidepressants, barbiturates, and opiate compounds are also frequently abused.

Urine-specific screening tests for drugs range from simple immunoassay tests to complex analytical procedures. But the speed and sensitivity of immunoassays have made them the preferred method for detecting drugs in urine.

The TOX Drug Screen, 94600 uses distinct immunoassays to simultaneously detect drug and/or urinary metabolites of as many as nine different drug classes. Using monoclonal antibodies that are specific for the metabolites of these drug classes ensures a high level of sensitivity and specificity.

Approximately 15 minutes after the specimen is added, the Quidel Triage MeterPro screen displays results, which are stored in the system’s memory to display or print when needed. The results can also be transmitted to the laboratory or hospital information system.

Source: Seeking Alpha, June 19, 2019

Recent Headlines

Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Fast-acting insulin aspart may simplify mealtime dosing
Simple change in dosage and route may improve a century-old vaccine
Neurodevelopmental deficits detected in Colombian toddlers
Improvement in overall survival fails to reach statistical significance